Related Experiment Video
Updated: Mar 14, 2026
07:25
Visualization of Pseudomonas aeruginosa within the Sputum of Cystic Fibrosis Patients
Published on: July 16, 2020
3.7K
Pneumococcal vaccines for cystic fibrosis
Laura Burgess1, Kevin W Southern
1Alder Hey Children's NHS Foundation Trust, Eaton Road, Liverpool, UK, L12 2AP.
The Cochrane Database of Systematic Reviews
|September 23, 2016
Summary
No clinical trials were found to evaluate pneumococcal vaccines for cystic fibrosis patients. Further research, like epidemiological studies, is needed to determine vaccine efficacy in this population.
Area of Science:
- Medical Research
- Vaccinology
- Pulmonology
Background:
- Invasive pneumococcal disease (IPD) causes significant mortality globally.
- Routine childhood pneumococcal vaccination is implemented in many countries.
- Pneumococcal vaccination is recommended for individuals with cystic fibrosis (CF) in the USA and UK, despite uncommon IPD incidence.
Purpose of the Study:
- To assess the efficacy of pneumococcal vaccines in reducing morbidity in people with cystic fibrosis.
Main Methods:
- Searched the Cochrane Cystic Fibrosis and Genetic Disorders Group Trials Register.
- Contacted pharmaceutical manufacturers of pneumococcal vaccines.
- Included randomized and quasi-randomized controlled trials comparing pneumococcal vaccination with placebo or no vaccination in CF patients.
Main Results:
- No relevant trials were identified for inclusion in this review.
Conclusions:
- No conclusions can be drawn regarding the efficacy of pneumococcal immunization in reducing morbidity or mortality in cystic fibrosis patients due to the absence of trials.
- Future randomized controlled trials are unlikely given widespread childhood vaccination schedules.
- Epidemiological studies may provide insights into pneumococcal vaccine efficacy in the cystic fibrosis population.
Related Concept Videos
01:24Cystic Fibrosis: Management
602
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
Sinus disease and chronic...
602
01:30Pneumonia V: Nursing management and Prevention
3.9K
Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
3.9K
01:23Cystic Fibrosis: Pathogenesis
999
Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
999
01:30Pneumonia III: Complications and Assessment
1.1K
Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
1.1K
01:29Pneumonia II: Pathophysiology
3.8K
The pathophysiology of pneumonia involves the following steps:
3.8K
01:30Pneumonia I: Introduction
1.2K
Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
1.2K